Cell Expansion Market

Cell Expansion Market Size (2023 to 2028)

The global cell expansion market is predicted to value USD 50.07 billion by 2028 from USD 21.26 billion in 2023, growing at a CAGR of 18.68% during the forecast period.

The expansion of stem cells is a pre-requisite for stem cells or even fully differentiated cell populations to be genuinely beneficial in their utility as drug screening tools or even for core research purposes. Cell expansion is done by cloning, which implies the derivation of the state of cells or substances from the same cell or multiple varied sources. Various media, reagents, and supplements maintain the required environment for stem cell expansion. It may also involve the participation of healthy feeder populations or conditioned components taken off feeder cells.

MARKET DRIVERS:

YOY growth in the incidence of chronic diseases, growing R&D activities, and favorable government initiatives for regenerative medicine propel global cell expansion market growth.

The prevalence of infectious and chronic diseases is significantly growing. Cardiovascular diseases (CVDs) are the leading cause of death rate globally. According to the WHO, around 17.9 million people died from CVDs in 2016, representing 31% of global deaths. Companies operating in this market invest significant amounts in R&D to develop better solutions.

YOY growth in regenerative medicine is significantly favoring the growth of the cell expansion market. In addition, the growing number of research and development activities in the life sciences, supportive government proposals, and regenerative medicine research are further expected to favor the growth of cell expansion.

Growing incidence of cancer results in a considerable patient count, creating an opportunity for the manufacturers to focus more on R&D. In countries like India, Brazil, and China, biotechnology and pharmaceutical companies have grown prominently and are projected to accelerate the demand for cell expansion for research and development activities and pharma products production. 

The technological advancements are expected to support market expansion.

Companies have made several technological advancements to produce better results for cell expansion procedures driving market expansion. For instance, the Quantum Cell Expansion System is used to expand neurological stem cells and hMSC, helping better research in the fields. Therefore, new advancements in stem cell research and bioreactor processes are expected to help the market progress. 

MARKET RESTRAINTS:

Lack of skilled workforce and high-tech instrumentation are some of the major restraints to the global cell expansion market. However, the market clocks a robust CAGR of more than 18% and is set to expand further based on its diverse driving factors. The ethical concerns related to the use of cell expansion to develop new research results and clinical experimentation are a particular drawback to the advancement of the market. 

Impact of COVID-19 on the global cell expansion market:

The World Health Organization (WHO) declared the COVID-19 pandemic as an emerging health issue and has affected millions of lives, including the business sectors. The pandemic brought forth a significant economic crisis for various sectors. The disruptions in supply and demand chains of goods and the imposition of lockdowns and quarantines resulted in adverse mental and financial crises worldwide. The healthcare sector was most significantly impacted due to the rising influx of patients and the lack of proper care facilities. 

The sudden outburst of COVID-19 has positively influenced the cell expansion market.

Cell expansion products are like cell culture media, and instruments are used in COVID-19 research. Regenerative medicine and stem cell research are significant applications of cell expansion. Cell-based strategies, mainly mesenchymal stromal cells (MSCs), provide a promising approach to justifying the COVID-19 infection's side effects. MSCs are a promising tool for treating diseases, including immune dysregulation and broad tissue damage, with COVID-19 and multiple clinical trials launched. With COVID-19, stem cell therapies, particularly mesenchymal stem cell (MSC) appropriate therapies, have exhibited therapeutic potential, especially for newly existing diseases with no available treatments. 

REPORT COVERAGE:

This research report on the global cell expansion market has been segmented and sub-segmented into the following categories.

Cell Expansion Market - By Product:

• Instruments
• Consumables
• Disposables

The consumables segment is forecasted to lead the global cell expansion market during the forecast period based on the product. The mounting production of vaccines and other biologics in the biopharmaceutical and biotechnology industries aid in segment growth. The products created by cell expansion research are exceptionally vital in treating several new conditions and promoting revenue for the segment. 

The instruments segment is registered to have the fastest CAGR during the forecast period. The automated platforms' approach standardizes the process and advances process tracking while decreasing hands-on time.

The disposables segment is predicted to have a promising CAGR during the forecast period. The insignificant threat is relevant to the cross-contamination of laboratory equipment and the blooming pharmaceutical and biotechnology industry booming the cell expansion market growth.

Cell Expansion Market - By Cell Type:

• Human Cells
  • Stem Cells
  • Adult Stem Cells
    • Induced Pluripotent Stem Cells
    • Embryonic Stem Cells
    • Differentiated Cells
• Animal Cells

Based on the cell type, the human cells segment accounted for the leading share of the cell expansion market in 2022 and is expected to continue leading the market during the forecast period. The growth of this segment can be credited to the rising investments from public and private organizations for R&D on human cells, the growing usage of human stem cell applications in multiple fields, and the rising prevalence of chronic diseases. 

Under this segment, the human stem cells segment gained superior resistance and is expected to grow at a healthy CAGR from 2023 to 2028. In addition, automated, robotic, and closed production systems boost the global market growth. Furthermore, the newly found research and development in stem cell therapy to counter various diseases is expected to boost this segment further. 

Cell Expansion Market - By Application:

• Regenerative Medicine
• Stem Cell Research
• Cancer
• Cell-Based Research

The regenerative medicine segment accounted for the major share of the cell expansion market in 2022. For instance, cellular-based therapies have attained colossal popularity over regenerative medicine with stable improvements in injectable cell delivery systems for different clinical applications. In addition, the rising demand for the personalization of healthcare services is expected to further support the segment's rise.

However, the cancer research and the stem cell research segment are expected to show fast growth during the forecast period due to rising cases of stem cell research and the growing number of deaths due to cancer. According to WHO, cancer is a leading cause of death worldwide, with around 1 in every six deaths and 10 million cancer deaths reported in 2020. Therefore, the need for more treatment options is driving the segments. 

Cell Expansion Market - By End User:

• Hospitals
• Biotech and Pharma Companies
• Academic and Research Institutes

The biotech and pharma companies segment is anticipated to register the lead among all the segments during the forecast period. The segment growth is due to increasing consciousness about advanced personalized and other cell-based treatments. Therefore, the pharma and biopharma companies are involved in acquisitions to enlarge their production portfolio. For instance, in December 2019, Sartorius AG agreed to obtain 50% of Biological Industries' shares. The purchase outstretched Sartorius's cell culture media portfolio, particularly for cellular and gene therapies, regenerative medicine, and other developed therapies. 

The academic and research institutes segment is also expected to show significant growth during the forecast period owing to the rising R&D activities in cell expansion. In addition, the encouragement towards developing new cell expansion experiments, especially among students, is expected to help the segment's growth. 

Cell Expansion Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

The North American cell expansion market led the market in 2021 and accounted for a significant global market share. The dominance of the North American region is attributed to the presence of key market players, a relatively high number of registered treatments, and the increasing use of cartilage repair or regeneration to treat sports injuries and other accidents. 

The European cell expansion market held a substantial share of the global market in 2021 owing to rising awareness about blood-related disorders and the swift availability of treatment in terms of plasma fractionation. 

However, the Asia-Pacific cell expansion market is expected to outpace all other regions by clocking the highest CAGR during the forecast period, majorly because of a vast population base and companies looking to tap the region's market potential.

The Latin American cell expansion market is expected to grow steadily during the forecast period.

The Middle East and Africa cell expansion market is anticipated to register a moderate CAGR during the forecast period.

KEY MARKET PARTICIPANTS:

A few of the notable players operating in the cell expansion market profiled in the report include Beckman Coulter, Inc. (U.S.), Becton, Dickinson, and Company (U.S.), Corning, Inc. (U.S.), GE Healthcare (U.K.), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT, Inc. (U.S.), and Thermo Fisher Scientific, Inc. (U.S.).

RECENT MARKET HAPPENINGS:

• In October 2022, At the Cell & Gene Meeting on the Mesa, a pluripotent stem cell panel will be discussed. PSCs have great potential for treating a wide range of illnesses and ailments. However, the obstacles to scaling up PSC-derived cell therapies will be the subject of a session on October 13 at the Cell & Gene Meeting on the Mesa in Carlsbad, California.
• Seth Ettenberg, Ph.D., a panelist and the CEO of BlueRock Therapeutics, discussed the advantages of induced pluripotent stem cells with the Science Advisory Board (iPSCs). The iPSC-based platform used by clinical-stage engineered cell therapy startup BlueRock allows differentiated, mature cells to be reprogrammed back into iPSCs and use cutting-edge engineering to improve the therapeutic potential of these cells.
• In October 2022, Asymmetrex® Talks About the Impact Of New Technologies For Stem Cell Dosage Determination On Pharma, Gene Therapy, And Stem Cell Clinical Trials Outsourcing.
• James L. Sherley, M.D., Ph.D., President and CEO of Asymmetrex®, will talk about the effects of the recent release of technology for stem cell dosage on the clinical trials outsourcing sector on Wednesday, October 12, at Outsourcing in Clinical Trials New England 2022. Pharmaceutical medication development and stem cell this advancement will impact clinical trials in stem cell science and medicine.
• In October 2022, Lineage will expand its current GMP manufacturing facility in Israel while opening a new R&D facility in the United States. The opening of a new research and development (R&D) facility in Carlsbad, California, and the expansion of its Good Manufacturing Practice (GMP) manufacturing facility based in Jerusalem, Israel, were both announced today by Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The opening of Lineage's new facility in Carlsbad will increase the company's R&D capabilities in the United States and aid in the growth of existing and upcoming allogeneic cell transplant initiatives. In addition, expanding Lineage's Israel-based facility will improve the company's infrastructure, allow it to continue its continuing partnership with Roche and Genentech for RG6501, and develop and improve larger-scale clinical manufacturing procedures (OpRegen).